293 results on '"McMurray, John J.V."'
Search Results
2. Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
3. Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy: Rationale and Design of the PARACHUTE-HF Trial
4. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
5. Relevant adverse events and drug discontinuation of sacubitril/valsartan in a real-world Japanese cohort: REVIEW-HF registry
6. Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure
7. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function
8. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
9. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study
10. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
11. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction
12. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial
13. Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction
14. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
15. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
16. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial
17. Sex Differences in the Clinical Presentation and Natural History of Dilated Cardiomyopathy
18. Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
19. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel Paper
20. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
21. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial
22. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
23. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial
24. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
25. Clinical Features of Heart Failure With Normal Ejection Fraction: Insights From the ASIAN-HF Registry
26. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
27. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
28. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction
29. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER
30. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
31. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction
32. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
33. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
34. How to Manage Heart Failure With Preserved Ejection Fraction: Practical Guidance for Clinicians
35. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF
36. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
37. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF
38. Prognosis in Patients With Cardiogenic Shock Who Received Temporary Mechanical Circulatory Support
39. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER
40. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
41. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
42. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
43. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs
44. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
45. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
46. Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model
47. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF
48. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population
49. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure
50. Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.